跳至主要内容
临床试验/NCT05161897
NCT05161897已完成不适用

Individualized Nutrition Therapy for Preventing or Delaying Onset of Type-2 Diabetes

George Mason University2 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2022年8月25日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
30
试验地点
2
主要终点
Change in interstitial glucose concentrations [Time Frame: baseline, 10 days, 20 days, and 30 days]

研究概览

简要总结

The overall aim of this feasibility study is to conduct a randomized, controlled intervention providing adults with prediabetes either an individualized nutrition therapy (INT) intervention that contains individualized dietary goal-setting components, the goal being to improve blood glucose, reduce CVD risk factors, and therefore postpone the onset of diabetes and related cardiovascular disease, or standard-of-care generalized dietary recommendation (SOC). The hypothesis is that the INT arm will experience greater benefits in some or all of the following primary outcome variables: improvement in postprandial blood glucose, oral glucose tolerance test, fasting insulin, and calculated insulin sensitivity (HOMA) in individuals with prediabetes. Secondary outcome variables are improved markers of inflammation, antioxidant status, blood lipids, blood pressure, and endothelial function.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
None

入排标准

年龄范围
45 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Ages 45-65 years
  • Any race or ethnicity
  • Those who have or may have pre-diabetes (will be screened to confirm)
  • HbA1c level between 5.7%-6.4% (will be screened to confirm)
  • BMI between 25 and 39.9 kg/m2
  • Taking stable doses of antihypertensive and/or cholesterol-lowering medications for 3 months or more prior to being enrolled in the study

排除标准

  • Pregnant or lactating
  • Individuals outside of the HbA1c and BMI inclusion ranges
  • Those with active cancer, thyroid, kidney, liver, and pancreatic diseases
  • Heavy cigarette smokers (25 cigarettes per day or more)
  • Heavy drinkers (>12 alcoholic drinks per week on average)
  • Taking more than one hypoglycemic agent (blood sugar lowering medications)
  • Having major dietary restrictions
  • Participating in any weight loss or dietary program/taking prescribed appetite suppressants
  • Participating in another investigational study at the same time as this study
  • Anyone who refuses to follow dietary recommendations
  • Anyone who refuses to wear the continuous glucose monitoring device as instructed
  • Anyone who will not fill out their food dairy and automated self-administered dietary assessment tool

结局指标

主要结局

Change in interstitial glucose concentrations [Time Frame: baseline, 10 days, 20 days, and 30 days]

时间窗: baseline, 10 days, 20 days, and 30 days

Evaluating change in 24hr interstitial glucose concentrations and glycemic variability from baseline measure using a Continuous Glucose Monitoring (CGM) device

Change in insulin sensitivity [Time Frame: baseline, 10 days, 20 days, and 30 days]

时间窗: baseline, 10 days, 20 days, and 30 days

Change in insulin sensitivity from baseline measure will be assessed using the homeostatic model of insulin resistance (HOMA-IR) and insulin secretion (HOMA-β)

Change in glucose tolerance [Time Frame: baseline, 10 days, 20 days, and 30 days]

时间窗: baseline, 10 days, 20 days, and 30 days

Change in glucose tolerance from baseline measures will be assessed using an oral glucose tolerance test

次要结局

  • Change in inflammation status [Time Frame: baseline, 10 days, 20 days, and 30 days](baseline, 10 days, 20 days, and 30 days)
  • Change in markers of endothelial function [Time Frame: baseline, 10 days, 20 days, and 30 days](baseline, 10 days, 20 days, and 30 days)
  • Change in blood pressure [Time Frame: baseline, 10 days, 20 days, and 30 days](baseline, 10 days, 20 days, and 30 days)
  • Change in atherogenic risk ratios [Time Frame: baseline, 10 days, 20 days, and 30 days](baseline, 10 days, 20 days, and 30 days)
  • Change in lipid profiles [Time Frame: baseline, 10 days, 20 days, and 30 days](baseline, 10 days, 20 days, and 30 days)
  • Change in antioxidant status [Time Frame: baseline, 10 days, 20 days, and 30 days](baseline, 10 days, 20 days, and 30 days)
  • Change in dietary intake [Time Frame: baseline, 10 days, 20 days, and 30 days](baseline, 10 days, 20 days, and 30 days)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Raedeh Basiri

Assistant Professor

George Mason University

研究点 (2)

Loading locations...

相似试验